Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

JUHI FATIMA NAYEEM

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1689767568
CMS profile
349240
Location
LAUREL, MD

General Payments · PY2018–2024

$8,459.15

  • Reported across 386 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$1,386.52

31 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,386.52 31

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
ITI, Inc. $650.23 16
Alkermes, Inc. $303.24 5
Janssen Pharmaceuticals, Inc $160.90 5
E.R. Squibb & Sons, L.L.C. $122.02 1
Teva Pharmaceuticals USA, Inc. $78.16 2
Neurocrine BioSciences, Inc. $37.58 1
ABBVIE INC. $34.39 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $2,765.18 141
PY2019 $2,239.16 158
PY2020 $313.98 14
PY2022 $314.33 6
PY2023 $1,439.98 36
PY2024 $1,386.52 31

Payment records · PY2024 (31)

Sorted by paying entity, then date · as published by CMS

Program year 2024 20182019202020222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $34.39 06/17/2024 Food and Beverage Undisputed 01/23/2026 1105105370 CMS
Alkermes, Inc. $28.66 02/23/2024 Food and Beverage Undisputed 01/23/2026 1120561644 CMS
Alkermes, Inc. $110.90 04/09/2024 Food and Beverage Undisputed 01/23/2026 1120561646 CMS
Alkermes, Inc. $26.71 10/03/2024 Food and Beverage Undisputed 01/23/2026 1120561648 CMS
Alkermes, Inc. $109.29 10/16/2024 Food and Beverage Undisputed 01/23/2026 1120561650 CMS
Alkermes, Inc. $27.68 11/15/2024 Food and Beverage Undisputed 01/23/2026 1120561652 CMS
E.R. Squibb & Sons, L.L.C. $122.02 09/24/2024 Food and Beverage Undisputed 01/23/2026 1101614924 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $27.44 01/27/2024 Food and Beverage Undisputed 01/23/2026 1143285145 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $24.95 02/12/2024 Food and Beverage Undisputed 01/23/2026 1143285148 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $24.21 03/18/2024 Food and Beverage Undisputed 01/23/2026 1143285152 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $111.04 05/30/2024 Food and Beverage Undisputed 01/23/2026 1143285156 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $24.99 08/27/2024 Food and Beverage Undisputed 01/23/2026 1143285159 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $110.00 09/04/2024 Food and Beverage Undisputed 01/23/2026 1143285163 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $22.88 09/06/2024 Food and Beverage Undisputed 01/23/2026 1143285167 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $30.11 09/17/2024 Food and Beverage Undisputed 01/23/2026 1143285170 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $28.80 10/04/2024 Food and Beverage Undisputed 01/23/2026 1143285174 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $27.97 10/23/2024 Food and Beverage Undisputed 01/23/2026 1143285178 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $27.13 10/31/2024 Food and Beverage Undisputed 01/23/2026 1143285181 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $26.05 11/08/2024 Food and Beverage Undisputed 01/23/2026 1143285185 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $34.59 11/13/2024 Food and Beverage Undisputed 01/23/2026 1143285189 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $74.81 11/13/2024 Food and Beverage Undisputed 01/23/2026 1143285192 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $27.96 11/26/2024 Food and Beverage Undisputed 01/23/2026 1143285196 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $27.30 12/06/2024 Food and Beverage Undisputed 01/23/2026 1143285199 CMS
Janssen Pharmaceuticals, Inc $25.02 01/30/2024 Food and Beverage Undisputed 01/23/2026 1078045566 CMS
Janssen Pharmaceuticals, Inc $31.47 03/27/2024 Food and Beverage Undisputed 01/23/2026 1078045574 CMS
Janssen Pharmaceuticals, Inc $37.04 06/05/2024 Food and Beverage Undisputed 01/23/2026 1078045568 CMS
Janssen Pharmaceuticals, Inc $36.98 10/25/2024 Food and Beverage Undisputed 01/23/2026 1078045594 CMS
Janssen Pharmaceuticals, Inc $30.39 12/03/2024 Food and Beverage Undisputed 01/23/2026 1078045580 CMS
Neurocrine Biosciences, Inc. $37.58 02/15/2024 Food and Beverage Undisputed 01/23/2026 1150816548 CMS
Teva Pharmaceuticals USA, Inc. $40.98 11/22/2024 Food and Beverage Undisputed 01/23/2026 1151601694 CMS
Teva Pharmaceuticals USA, Inc. $37.18 11/25/2024 Food and Beverage Undisputed 01/23/2026 1151601696 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.